Advertisement

Thymosins and anti-thymosins: Properties and clinical applications

  • Allan L. Goldstein
  • Richard S. Schulof
  • Paul H. Naylor
  • Nicholas R. Hall
Growth Factors and Hormones
  • 34 Downloads

Abstract

For years, scientists have searched for ways to trigger the body's own defenses against cancer and other diseases associated with abnormal immunity. This search has led to the discovery of a number of important new biological and chemical substances that augment, direct or restore many of the normal defenses of the body. These substances are in essence the natural drugs of the body that endow us with immunity and resistance to disease.

Now called biological response modifiers (BRMs), most of these 'lsnew medicines’, such as thymosins, lymphokines, and interferons, occur naturally in the body, while others, synthetic immunomodulators and thymomimetic agents (drugs that mimic thymic function) have been created in the laboratory. Previously, therapeutic drug development in this area relied upon chemical synthesis or introduction of bacterial adjuvants, or modified viral compounds and substances, which were foreign to the body. Therefore, they did not and do not rely upon or use the body's natural immune and biological response systems for protection against disease, function and response to the environment.

Although scientists have known about BRMs for years, isolating and purifying them so that they could be used to treat diseases has been extremely difficult. Many of these substances, such as the lymphokines, occur in the body in minute amounts and normally do not circulate in the blood. The development of new technologies for isolation and large scale synthesis, e.g. solid phase peptide synthesis, high-pressure liquid chromatography microsequencing and genetic engineering, has now permitted scientists to isolate, purify, and synthesize BRMs in sufficiently large quantities to allow human clinical trials. In this paper we will focus on the potential clinical applications of the thymosins and anti-thymosins.

Key words

Thymus Thymosins Neuroendocrine Cancer Aging AIDS 

References

  1. 1.
    Hall N R, McGillis J P, Spangelo B L, Goldstein A L: Evidence that thymosins and other biologic response modifiers can function as neuroactive immunotransmitters.J Immun 135 (Suppl 2), 806s (1985).Google Scholar
  2. 2.
    Goldstein A L (ed):Thymic Hormones and Lymphokines: Their Chemistry and Clinical Applications. New York, Plenum Press, (1984).Google Scholar
  3. 3.
    Oates K K, Goldstein A L: Thymosins.Trends Pharmac Sci 3, 347 (1984).CrossRefGoogle Scholar
  4. 4.
    Zatz M M, Goldstein A L: Thymosins, lymphokines, and the immunology of aging.Gerontology 31, 263 (1985).PubMedCrossRefGoogle Scholar
  5. 5.
    Haritos A A, Goodall G J, Horecker B L: Prothymosin alpha: isolation and properties of the major immunoreactive form of thymosin alpha 1 in rat thymus.Proc Natl Acad Sci USA 81, 1008 (1984).PubMedCrossRefGoogle Scholar
  6. 6.
    Goldstein A L, Slater F D, White A: Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin).Proc Natl Acad Sci USA 56, 1010 (1966).PubMedCrossRefGoogle Scholar
  7. 7.
    Hooper J A, McDaniel M C, Thurman G B, Cohen G H, Schulof R S, Goldstein A L: Purification and properties of bovine thymosin.Ann NY Acad Sci 249, 125 (1975).PubMedCrossRefGoogle Scholar
  8. 8.
    Zatz Met al: InBiological Responses to Cancer, pp. 219–247. Plenum Press (1982).Google Scholar
  9. 9.
    Huang K Y, Kind P D, Jagoda E M, Goldstein A L: Thymosin treatment modulates production of interferon.J Interferon Res 1, 411 (1981).PubMedGoogle Scholar
  10. 10.
    Ishitsuka H, Yagi Y: InThymic Hormones and Lymphokines, pp. 425–438. New York, Academic Press (1984).Google Scholar
  11. 11.
    Goldstein A L, Low T L, McAdoo M, McClure J, Thurman G B, Rossio J, Lai C Y, Chang D, Wang S S, Harvey C, Ramel A H, Meienhofer J: Thymosin alpha 1: isolation and sequence analysis of an immunologically active thymic polypeptide.Proc Natl Acad Sci USA 74, 725 (1977).PubMedCrossRefGoogle Scholar
  12. 12.
    Caldarella J, Goodall G J, Felix A M, Heimer E P, Salvin S B, Horecker B L: Thymosin alpha 11: a peptide related to thymosin alpha 1 isolated from calf thymosin fraction 5.Proc Natl Acad Sci USA 80, 7424 (1983).PubMedCrossRefGoogle Scholar
  13. 13.
    Low T L, Hu S K, Goldstein A L: Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations.Proc Natl Acad Sci USA 78, 1162 (1981).PubMedCrossRefGoogle Scholar
  14. 14.
    Hannappel E, Davoust S, Horecker B L: Thymosins beta 8 and beta 9: two new peptides isolated from calf thymus homologous to thymosin beta 4.Proc Natl Acad Sci USA 75, 1708 (1982).CrossRefGoogle Scholar
  15. 15.
    Erickson-Viitanen S, Ruggieri S, Natalini P, Horecker B L: Thymosin beta 10, a new analog of thymosin beta 4 in mammalian tissues.Arch Biochem Biophys 225, 407 (1983).PubMedCrossRefGoogle Scholar
  16. 16.
    Ruggieri S, Erickson-Viitanen S, Horecker B L: Thymosin beta arg10, a major variant of thymosin beta 10 in rabbit tissues.Arch Biochem Biophys 226, 388 (1983).PubMedCrossRefGoogle Scholar
  17. 17.
    Wara D W, Martin N L, Wara W M, Goldstein A L, McClure J E: Thymosin α1 levels in children with primary cellular immunodeficiency and in adults with malignancy; in Serrou,Current Concepts in Human Immunology and Cancer Immunomodulation. New York, Elsevier Biomedical Press (1982).Google Scholar
  18. 18.
    Wara D W, Goldstein A L, Doyle N E, Ammann A J: Thymosin activity in patients with cellular immunodeficiency,New Engl J Med 292, 70 (1975).PubMedGoogle Scholar
  19. 19.
    Ohta Y, Tezuka E, Tamura S, Yagi Y: Thymosin alpha 1 exerts protective effect against the 5-FU induced bone marrow toxicity.Int J Immunopharmac 7, 761 (1985).CrossRefGoogle Scholar
  20. 20.
    Talmadge J E, Uithoven K A, Lenz B F, Chirigos M: Immunomodulation and therapeutic characterization of thymosin fraction five.Cancer Immun Immunother 18, 185 (1984).Google Scholar
  21. 21.
    Schulof R S, Lloyd M J, Cleary P A, Palaszynski S R, Mai D A, Cow J W Jr, Alabaster O, Goldstein A L: A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer.J Biol Response Modif 4, 147 (1985).Google Scholar
  22. 22.
    Lavastida M T, Goldstein A L, Daniels J C: Thymosin administration in autoimmune disorders.Thymus 2, 287 (1981).PubMedGoogle Scholar
  23. 23.
    Jacobs R Pet al: InProceedings Thymic Hormone Therapy, Vol. 16, pp. 267–276. New York, Raven Press (1985).Google Scholar
  24. 24.
    Naylor P H, Goldstein A L: The thymus-AIDS connection.Bioassays 1, 64 (1984).Google Scholar
  25. 25.
    Goldstein, A L, Naylor P H, Schulof R S, Simon G L, Sztein M B, Kessler C M, Robert-Gunoff M, Gallo R C: Thymosin in the staging and treatment of HLTV-III positive homosexuals and hemophilliacs with AIDS-related immune dysfunction, inAIDS-Associated Syndromes, pp. 125–140. New York, Plenum Press.Google Scholar
  26. 26.
    Frasca D, Adorini L, Doria G: Enhancement of helper and suppressor T cell activities by thymosin alpha 1 injection in old mice.Immunopharmacology 10, 41 (1985).PubMedCrossRefGoogle Scholar
  27. 27.
    Ershler W B, Moore A L, Hacker M P, Ninomiya J, Naylor P, Goldstein A L: Specific antibody synthesisin vitro. II. Age-associated thymosin enhancement of antitetanus antibody synthesis.Immunopharmacology 8, 69 (1984).PubMedCrossRefGoogle Scholar
  28. 28.
    Hall N R, Goldstein A L: The thymus-brain connection: interactions between thymosin and the neuroendocrine system.Lymphokine Res 2, 1 (1983).PubMedGoogle Scholar
  29. 29.
    Rebar R W, Miyake A, Low T L, Goldstein A L: Thymosin stimulates secretion of luteinizing hormone-releasing factor.Science 214, 669 (1981).PubMedCrossRefGoogle Scholar
  30. 30.
    Healy D L, Hodgen G D, Schulte H M, Chrousos G P, Loriaux D L, Hall N R, Goldstein A L: The thymus-adrenal connection: thymosin has corticotropin-releasing activity in primates.Science 222, 1353 (1983).PubMedCrossRefGoogle Scholar
  31. 31.
    Kilby A L, Ershler W B:Clin Immun 5, 125 (1984).Google Scholar
  32. 32.
    Olusi S O, Thurman G B, Goldstein A L: Effect of thymosin on T-lymphocyte rosette formation in children with kwashiorkor.Clin Immun Immunopath 15, 687 (1980).PubMedCrossRefGoogle Scholar
  33. 33.
    Suh B Y, Naylor P H, Goldstein A L, Rebar R W: Modulation of thymosin beta 4 by estrogen.Am J Obstet Gynec 151, 544 (1985).PubMedGoogle Scholar
  34. 34.
    Sarin P S, Sun D K, Thornton A H, Naylor P H, Goldstein A L: Neutralization of HTLV-III/LAV replication of antiserum to thymosin α1.Science 232, 1135 (1986).PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 1986

Authors and Affiliations

  • Allan L. Goldstein
    • 1
  • Richard S. Schulof
    • 2
  • Paul H. Naylor
    • 1
  • Nicholas R. Hall
    • 1
  1. 1.Department of BiochemistryThe George Washington University School of MedicineWashington, D.C.U.S.A.
  2. 2.Department of MedicineThe George Washington University School of MedicineWashington, D.C.U.S.A.

Personalised recommendations